(Z)-2-Cyanoethyl 2-(4-cyano-2-methoxybenzylidene)-3-oxobutyrate

List of basic product information

nature

the product is the key synthetic intermediate of non-nellione (Finerenone), which belongs to the substituted benzylidene-β-dicarbonyl compound. The structure also contains cyano (-CN), methoxy (-OCH), cyanoethyl ester and benzylidene conjugated system, which makes it have multi functional reaction sites in organic synthesis. Soluble in common organic solvents (such as dichloromethane, ethyl acetate, DMF, etc.), the solubility in water has not been disclosed by the system, and it is usually recommended to dispose of organic intermediates under conventional moisture-proof, light-proof and low-temperature sealing conditions.

Computational chemistry data are available: TPSA is about 100.18 Ų,LogP is about 2.0, hydrogen bond acceptors are 6, and rotatable bonds are 6. These parameters suggest that the molecule has a certain degree of lipophilicity, but a number of polar functional groups in polar organic solvents should have a better solubility.

Use

this intermediate is specific for the synthetic route of non-nelliones (Finerenone).

Fenellidone is a non-steroidal selective mineralocorticoid receptor antagonist used for the treatment of chronic kidney disease associated with type 2 diabetes. In the synthesis process of non-nelidone, intermediate 004 participates in the subsequent addition/cyclization reaction as a benzylidene fragment, and constructs the 1,6-naphthyridine core of non-nelidone with another intermediate (such as 005). The product can also be used as an impurity reference or synthetic standard in the study of non-nellione related impurities.

Safety Information

there are some differences in the available safety data, and the operation should be based on the current version of SDS provided by the supplier:

some sources are labeled as non-dangerous goods (Not hazardous material), and the DOT/IATA column in the transportation information is “non-dangerous goods”.

Some sources give the GHS07 classification (Warning), and the risk statements include H302 (harmful if swallowed), H315 (causing skin irritation), and H319 (causing severe eye irritation).

Corresponding precautions include: thoroughly cleaning after operation (P264), avoiding inhalation/ingestion (P270), wearing protective gloves/eye mask/mask (P280), thoroughly cleaning after skin contamination (P302 + P352), and carefully rinsing with water for several minutes after eye contact (P305 + P351 + P338).

Suggested operation specifications: operate in a well-ventilated area, wear protective gloves, goggles and laboratory clothes to avoid dust generation and inhalation; keep the container sealed and away from strong oxidants and strong acid and alkali environments during storage. As the product is an intermediate for research/production, it should not be used for food, cosmetics or direct human use.

Shanghai Lizhuo (Lizhuo Pharmaceutical) production advantages and capacity

Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. (Shanghai Lizhuo Pharmaceutical Technology Co., Ltd.) is a high-tech enterprise focusing on the research and development, production and sales of high value-added pharmaceutical intermediates and APIs. https://www.shlzpharma.com/ .

Core advantages

1.

Non-nellione intermediate product line complete coverage. The company has systematically laid out a complete set of key intermediates for non-nellione. Intermediate 004(CAS 1050477-39-8) is a member of its core product sequence, forming upstream and downstream supporting supply capabilities with intermediates such as 002, 006, 007 and 008, which is convenient for customers to complete multi-step procurement and process connection of synthetic raw materials within the same supplier system.

2.

Industrial scale production has been achieved. According to the company’s public information, Shanghai Loulan has successfully realized the industrial scale production (industrial-scale mass production) of non-nellidone and villisigua (Vericiguat) key intermediates, and has completed the transformation from laboratory process to ton/scale delivery, with stable commercial supply capacity.

3.

Quality and supply stability are validated by the market. The company disclosed that the relevant high-purity intermediate products have been widely recognized by customers at home and abroad because of their excellent quality and stable supply since they were launched. The standard purity of the product can meet the level of ≥ 98.5%, and supports packaging specifications such as 10kg plastic barrels.

4.

Research and development drive and flexible production lines. The company to technological innovation as the driving force, continuous investment in research and development, production line with flexible deployment capabilities, according to order demand to adjust production arrangements, to adapt to a variety of demand scenarios from custom batch to commercial tons.

Capacity and Supply Description

regarding the specific annual production capacity tonnage of intermediate 004, the precise number is not disclosed in public channels at present. However, judging from the company’s disclosed “non-nellione intermediate industrial scale production” status, multi-variety parallel supply capacity and 10kg packaging specifications, Shanghai Loulan has a stable commercial batch delivery capacity, which can meet the continuous demand of API enterprises for intermediate 004 from the clinical stage to the commercialization stage. Specific capacity margin and delivery cycle recommendations through the official website. https://www.shlzpharma.com/ direct contact confirmation.

Welcome to visit our official website: https://www.shlzpharma.com/